Tilray's $207M Record Q3: How Beverages Saved a Cannabis Giant

Tilray Brands, once the most-shorted cannabis stock on the public market, just delivered the clearest proof yet that the company's multi-year pivot away from pure-play cannabis is working. The Canadian conglomerate reported record net revenue of $206.7 million for its fiscal 2026 third quarter — an 11% year-over-year increase, a 19% jump in adjusted EBITDA, and the kind of margin trajectory that turns a turnaround story into an investment case.

The quarter's most important story wasn't cannabis at all. It was the combination of a reshaped beverage portfolio, a rapidly expanding German medical cannabis business, and disciplined cost management — a three-engine strategy that helped Tilray narrow its net loss to $25.2 million, down from $793.5 million in the same period a year earlier.

The Numbers That Moved the Stock

Tilray's Q3 fiscal 2026 report, released April 1, came in ahead of Wall Street expectations on nearly every line. Revenue beat consensus. Gross profit expanded to $55 million, up 6% year-over-year. Adjusted earnings per share printed at $0.02 — against analyst estimates of a loss. And the company reaffirmed full-year adjusted EBITDA guidance of $62 million to $72 million, implying 13% to 31% growth over fiscal 2025.

More important than the beat: Tilray reported positive adjusted EBITDA across all four business segments — beverage, cannabis, distribution, and wellness. That's a structural milestone. For years, cannabis analysts have asked whether Tilray's scale was a durable advantage or merely a revenue line hiding deep segment losses. Q3 provided the first clean answer.

International Cannabis, Mostly Germany, Is the Growth Engine

The segment that surprised most was international cannabis. Revenue there jumped 73% year-over-year to $24.1 million, driven almost entirely by Germany, where April 2024's partial legalization continues to expand the medical cannabis patient base at a pace few operators anticipated. German medical flower sales from Tilray doubled in volume during the quarter.

Germany is now one of the most-watched cannabis growth markets in the world. The country's reform dramatically lowered barriers to medical cannabis access, removed prescription marijuana from narcotics scheduling, and paved the way for private-physician prescribing. Tilray, with its European manufacturing footprint and EU-GMP certified supply chain, has been positioned to capture demand since long before the policy change. The payoff has arrived.

Other European markets — Portugal, Poland, the UK — contributed incremental growth. Combined, international cannabis is the fastest-growing segment of Tilray's business and now carries materially better gross margins than its Canadian operations.

The Beverage Pivot Is Paying Off

The second turnaround lever is beverages. Tilray has spent the last three years buying craft beer, spirits, and non-alcoholic brands — culminating in its $500 million 2026 acquisition of BrewDog's Americas business. That deal more than doubled Tilray's beverage footprint in the U.S. and gave the company a cash-generating platform that is not regulated as cannabis under federal law.

In Q3, the beverage segment posted meaningful margin recovery after a challenging 2025. Execution on supply-chain optimization, portfolio rationalization, and pricing discipline flowed through to the bottom line. Management indicated the segment is now operating at or near profitability on an adjusted basis — no small feat in a consumer beverage category that has punished national brands far larger than Tilray's.

Beverages matter strategically for a reason beyond the income statement: they give Tilray dollar-denominated revenue, U.S. retail distribution, and a vehicle to launch THC beverages the moment federal rescheduling makes that possible at scale.

Cannabis Sales at Home: Tougher Story

The news wasn't uniformly positive. Tilray's Canadian cannabis business continues to operate in an oversupplied domestic market with margin pressure from value-tier competitors and retailer private-label expansion. Revenue was essentially flat, and market share gains in premium segments were partially offset by softness in mainstream dried flower.

That softness is hardly unique to Tilray. Canopy Growth, reporting its Q3 results for the quarter ending December 31, 2025, posted net revenue of $54.6 million — down about 0.3% year-over-year. Adjusted losses narrowed sharply, but revenue growth remains elusive for Canadian LPs. Canada's challenges are structural: too many licenses, price compression, limited export optionality, and consumer habits that have matured faster than industry capacity.

What This Means for Cannabis Investors

The Tilray results redefine what "winning" looks like for the first wave of public cannabis companies. Growth will not come uniformly from domestic adult-use markets. It will come from a combination of European medical expansion, disciplined adjacent-category M&A (beverages, wellness), and cost structure that can survive another two to three years of slow U.S. federal reform.

For investors, the immediate signal is that Tilray's operational case no longer depends on rescheduling. That's a meaningful de-risking. With positive segment-level EBITDA, $200 million+ quarterly revenue, and a clean path to fiscal 2026 guidance, Tilray is no longer priced as a binary bet on Schedule III. It's a diversified consumer-products company with cannabis upside.

For the broader sector, Tilray's story is a useful template. The pure-play cannabis model — bet everything on plant-touching U.S. scale — has stalled for multistate operators wrestling with 280E, expensive capital, and state-by-state regulatory complexity. Tilray's hybrid approach (federally legal beverages + internationally scalable medical cannabis + patient Canadian adult-use presence) looks increasingly like the durable strategy until federal reform materializes.

Looking Forward to Q4 and FY 2026

Management guided to continued top-line growth in Q4, supported by beverage seasonality and continued German cannabis momentum. The company expects to finish fiscal year 2026 (ending May 31) with record revenue, record adjusted EBITDA, and segment-level profitability across the portfolio.

The bigger question is capital allocation in FY 2027. With a cleaner balance sheet, improving cash generation, and a restructured share count, Tilray has optionality it hasn't enjoyed in years — to invest in U.S. hemp-derived THC beverages, build out European distribution, or pursue another accretive acquisition.

Key Takeaways

• Tilray posted record Q3 revenue of $206.7 million, an 11% YoY increase with all four segments at positive adjusted EBITDA.
• International cannabis revenue jumped 73%, led by Germany, where medical flower volume doubled.
• The 2026 BrewDog Americas acquisition helped beverage margins recover to near-profitability.
• Net loss narrowed dramatically to $25.2 million from $793.5 million a year earlier.
• Tilray's hybrid model — federally legal beverages plus international medical cannabis — is emerging as the most durable post-2025 cannabis strategy.

Explore cannabis news, find dispensaries, and join the community at Budpedia.